Almazed Company enters the Sudanese market with new pharmaceutical varieties of high quality

Published In: 12-10-2024

Dr. Al-Tohami Ramadan, Chairman of the Board of Directors of Al-Mazed Company, confirmed that his company's group will introduce four new and high-quality pharmaceutical varieties that will be released for the first time in the Sudanese pharmaceutical market.

 

His Excellency pointed out that these pharmaceutical classes include levoflexacin, a broad-spectrum antibiotic under the trade name (Naglovic 750mg) and atrophestatin lowering the level of lipids in the blood under the trade name (Satogler 10mg) and (Satogler 20mg). And Glimpride for the treatment of high blood sugar level under the brand name (Glimerazen 4mg).

 

His Excellency stressed that these four varieties will be downloaded with the highest quality and continuously to contribute in an excellent way to improving the health status of patients in Sudan and reducing the exacerbation of the disease.